Paper Details

  1. Home
  2. Paper Details

A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis.

Author: FranssenM J, GribnauF W, van de PutteL B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Diflunisal and phenylbutazone were both effective in treating ankylosing spondylitis. Diflunisal had a more pronounced and rapid analgesic effect, while phenylbutazone was more effective in increasing axial mobility. Both drugs had a similar safety profile, with gastrointestinal side effects being the most common.
Paper Details　
Original Abstract of the Article :
A 12-week double-blind randomized drug trial followed by an open extension period of 36 weeks was carried out in 38 male patients with ankylosing spondylitis (AS) to compare the efficacy and safety of diflunisal (500 mg twice daily) and phenylbutazone (200 mg twice daily). Both drugs proved to be ef...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02032359

データ提供：米国国立医学図書館（NLM）

Diflunisal and Phenylbutazone: A Double-Blind Trek Through Ankylosing Spondylitis

Ankylosing spondylitis (AS), a chronic inflammatory disease, is a desert of pain and stiffness for those who suffer from it. This double-blind study, conducted over a 12-week period, explores the efficacy and safety of two nonsteroidal anti-inflammatory drugs (NSAIDs), diflunisal and phenylbutazone, in treating AS. It's like comparing two different paths through a desert, seeking the most effective route to alleviate the symptoms of AS. Researchers found both drugs to be effective in improving symptoms, but with slightly different profiles. Diflunisal provided rapid pain relief, while phenylbutazone was more effective in increasing axial mobility. The research highlights the potential of these NSAIDs in managing AS, offering a glimmer of hope in the desert of chronic pain.

Finding the Right Path: Navigating AS Treatment

This study provides valuable insights into the diverse effects of two NSAIDs in treating AS. It's like understanding the different types of terrain in a desert, finding the right path for a specific journey. Diflunisal's rapid pain relief might be ideal for acute flares, while phenylbutazone's impact on mobility could be beneficial for long-term management. This research encourages a personalized approach to AS treatment, tailoring treatment strategies to individual needs.

A Balanced Journey: Managing AS with NSAIDs

This study emphasizes the importance of understanding both the benefits and risks associated with NSAID use. It's like carefully navigating a desert, acknowledging the potential pitfalls alongside the potential rewards. The study's findings highlight the need for close monitoring for potential side effects and open communication between patients and healthcare providers to ensure optimal outcomes. This research encourages a balanced approach to managing AS, finding a path towards improved quality of life while minimizing potential risks.

Dr. Camel's Conclusion

This study offers a valuable roadmap for navigating the desert of AS treatment, highlighting the potential benefits of both diflunisal and phenylbutazone. It's like finding a well-maintained path through the desert, ensuring a safe and comfortable journey towards managing this challenging disease. This research encourages continued exploration of NSAIDs and other treatment options, seeking a path towards a brighter future for those living with AS.

Date :
  1. Date Completed 1986-09-23
  2. Date Revised 2020-03-04
Further Info :

Pubmed ID

3524970

DOI: Digital Object Identifier

10.1007/BF02032359

Related Literature

Article Analysis
・Side Effects of diflunisal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.